H2 Receptor Antagonist: clinical trials recruiting now

Fewer than 3 recruiting trials found.

2

Recruiting trials

15

Conditions studied

7

US states with sites

11

Countries

Phase breakdown

Phase 1 1 Phase 2 1

Conditions being studied

Condition	Trials
Lung cancer	2
Colorectal Cancer (CRC)	1
Colorectal cancer	1
Dedifferentiated Liposarcoma	1
Gastric / Gastroesophageal Junction Adenocarcinoma	1
Gastric Cancer (GC)	1
Gastric Cancer Adenocarcinoma Metastatic	1
HNSCC	1
Leiomyosarcoma	1
Leiomyosarcoma (LMS)	1
Lung Neoplasm Malignant	1
Myxofibrosarcoma (MFS)	1
NSCLC	1
Non Small Cell Lung Cancer	1
Sarcoma	1

Recruiting trials involving H2 Receptor Antagonist

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
NCT06788912 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations

Common questions

How many recruiting trials involve H2 Receptor Antagonist?

2 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.